Empagliflozin in acute myocardial infarction: the EMMY trial( )

AIMS: Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and for death in patients with symptomatic heart failure. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking. METHODS AND RES...

Descripción completa

Detalles Bibliográficos
Autores principales: von Lewinski, Dirk, Kolesnik, Ewald, Tripolt, Norbert J, Pferschy, Peter N, Benedikt, Martin, Wallner, Markus, Alber, Hannes, Berger, Rudolf, Lichtenauer, Michael, Saely, Christoph H, Moertl, Deddo, Auersperg, Pia, Reiter, Christian, Rieder, Thomas, Siller-Matula, Jolanta M, Gager, Gloria M, Hasun, Matthias, Weidinger, Franz, Pieber, Thomas R, Zechner, Peter M, Herrmann, Markus, Zirlik, Andreas, Holman, Rury R, Oulhaj, Abderrahim, Sourij, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Fast Track Congress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622301/
https://www.ncbi.nlm.nih.gov/pubmed/36036746
http://dx.doi.org/10.1093/eurheartj/ehac494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622301/
https://www.ncbi.nlm.nih.gov/pubmed/36036746
http://dx.doi.org/10.1093/eurheartj/ehac494

Ejemplares similares